Lupin shares advanced 1.68% to ₹2,286.50 following the company's announcement of a significant regulatory milestone. According to reports from Business Standard, the United States Food and Drug Administration (USFDA) has approved Lupin's ranibizumab, Ranluspec (ranibizumab-hkdz) injection as an interchangeable biosimilar referencing to Lucentis, developed by Genentech.
As reported by Business Standard, Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes (PFS). The product is approved in both strengths available for Lucentis: 0.3 mg (0.05 mL of 6 mg/mL) and 0.5 mg (0.05 mL of 10 mg/mL). Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A, indicated for treating neovascular (wet) age-related macular degeneration and other eye conditions.
According to Business Standard, Vinita Gupta, CEO of Lupin, stated that the approval adds depth to their biosimilars portfolio, reflecting progress in complex biologics while expanding patient access to proven vision therapies. Dr. Cyrus Karkaria, President Biotechnology at Lupin, emphasized that the USFDA approval underscores their scientific expertise in biologics development and manufacturing, reinforcing commitment to expanding access to advanced, affordable therapies for patients worldwide.
Lupin has announced a strategic collaboration with Spanish pharmaceutical company Laboratorios ERN S.A. for the launch of Luforbec (beclometasone/formoterol) 100/6, a fixed-dose combination inhaler. As reported by Business Standard, the pressurised metered dose inhaler (pMDI) combines Lupin's respiratory expertise and manufacturing capabilities with ERN's established distribution network and customer relationships in the Spanish market. The collaboration marks a step forward in expanding access to respiratory care solutions in Europe, leveraging Lupin's global inhalation portfolio and ERN's local market presence to strengthen patient reach in Spain.
As reported by Business Standard, Lupin demonstrated strong financial performance in Q4 FY26 with consolidated profit after tax of ₹1,468.70 crore, representing an 87.72% increase from ₹782.40 crore in Q4 FY25. Net sales rose 32.9% to ₹7,391.91 crore in Q4 FY26 from ₹5,562.2 crore in Q4 FY25. The company operates as a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments.
